Substituierte Pyrazolopyrimidine als IRAK4-Inhibitoren

Details

Veröffentlichungs-Nr.

EP3800188

Aktenzeichen

EP19201191

Anmeldetag

2. Oktober 2019

Veröffentlichung

7. April 2021

Rechtsraum

EP

IPC

C07D487/04A61P25/00A61P29/00A61P35/00A61P37/00A61K31/519

Abstract

The present application relates to novel pyrazolopyrimidine derivatives for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases in humans and in animals, especially of proliferative disorders, autoimmune disorders, metabolic and inflammatory disorders characterized by an overreacting immune system, in particular rheumatological disorders, inflammatory skin disorders, cardiovascular disorders, lung disorders, eye disorders, neurological disorders, pain disorders and cancer, in human as well as of allergic and/or inflammatory diseases in animals, especially of atopic dermatitis and/or Flea Allergy Dermatitis, and especially in domestic animals, particularly in dogs.

Anmelder

Firmen

Bayer AG
Bayer Pharma Aktiengesellschaft

Land

🇩🇪 Deutschland

Fachgebiete